Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).

CONCLUSIONS: Results of this subgroup analysis suggest that treatment effects in the Asian patient subgroup are broadly consistent with the non-Asian population. PMID: 29450827 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29450827?dopt=Abstract

Source: Breast Cancer - February 15, 2018 Category: Cancer & Oncology Authors: Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z Tags: Breast Cancer Source Type: research